Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.5	1.12	3.15	12.26	0.19
Cash & Short-Term Investments	3.5	1.12	3.15	12.26	0.19
Cash Growth	211.68%	-64.30%	-74.33%	6215.06%	-43.13%
Receivables	0.12	0.1	0.28	0.44	-
Prepaid Expenses	0.36	0.51	0.55	0.81	0.02
Other Current Assets	1.36	0.55	1.33	2.15	0.14
Total Current Assets	5.34	2.29	5.3	15.66	0.35
Property, Plant & Equipment	-	-	-	-	0
Other Long-Term Assets	0.25	0.42	0.59	0.75	0
Total Assets	5.6	2.71	5.89	16.42	0.35
Accounts Payable	1.36	1.94	2.94	0.3	1.72
Accrued Expenses	0.55	0.54	2.23	3.41	0.19
Short-Term Debt	0.3	0.85	4.27	-	4.25
Current Portion of Long-Term Debt	-	-	-	12.75	-
Current Portion of Leases	-	-	0.03	0.02	0.03
Current Unearned Revenue	-	-	-	-	0.16
Other Current Liabilities	-	-	-	-	0.67
Total Current Liabilities	2.21	3.33	9.46	16.48	7.01
Long-Term Debt	-	-	0.14	4.44	-
Other Long-Term Liabilities	0.01	0.03	0.31	3.65	-
Total Liabilities	2.22	3.36	9.91	24.58	7.01
Common Stock	0	0	0	0	0
Additional Paid-In Capital	133.25	121.23	107.22	77.97	49.52
Retained Earnings	-129.54	-121.56	-110.93	-85.85	-55.96
Total Common Equity	3.71	-0.32	-3.71	-7.88	-6.44
Minority Interest	-0.33	-0.33	-0.32	-0.28	-0.22
Shareholders' Equity	3.38	-0.65	-4.03	-8.16	-6.66
Total Liabilities & Equity	5.6	2.71	5.89	16.42	0.35
Total Debt	0.3	0.85	4.43	17.21	4.27
Net Cash (Debt)	3.2	0.27	-1.29	-4.95	-4.08
Net Cash Growth	1090.16%	-	-	-	-
Net Cash Per Share	4.59	1.78	-107.24	-	-
Filing Date Shares Outstanding	1.41	0.49	0.09	0.02	239.47
Total Common Shares Outstanding	1.36	0.21	0.04	-	239.47
Working Capital	3.14	-1.04	-4.17	-0.82	-6.66
Book Value Per Share	2.74	-1.54	-104.24	-	-0.03
Tangible Book Value	3.71	-0.32	-3.71	-7.88	-6.44
Tangible Book Value Per Share	2.74	-1.54	-104.24	-	-0.03

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q